BeaconEquity.com releases investment report on Cord Blood America

BeaconEquity.com announces an investment report featuring umbilical cord blood stem cell preservation company Cord Blood America (OTCBB:CBAI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/CBAI

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity

Cord Blood America Inc. (CBAI), through its wholly owned subsidiaries CorCell Companies Inc. and Cord Partners Inc., markets a patented service to preserve umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments. Cryogenically preserved umbilical cord stem blood is shown to be effective in the treatment of approximately 75 diseases, including immune deficiencies, blood diseases and disorders, leukemia and acute anemia. CBAI's mission is to be the most respected, globally dominant stem cell preservation company in the industry.

In the report, the analyst notes:

"CBAI, moving toward achieving its goal of becoming a globally dominant stem cell storage company, recently signed a deal licensing its umbilical cord blood technology to AXM Pharma Inc., a China pharmaceutical and nutraceutical company.

"AXM Pharma, which has had a major presence in the Chinese pharmaceutical market for more than six years, owns six buildings totaling more than 200,000 square feet of space on its 13-acre biotech campus in Shenyang, China, dedicated for the venture. CBAI believes this creates the world's largest cord blood bank, with a capacity of more than 2 million samples to start."